Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Olema Pharmaceuticals (OLMA) Stock Price & Analysis
639 Followers
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.02 - $17.79
Previous Close$9.84
Volume547.96K
Average Volume (3M)838.15K
Market Cap
$550.39M
Enterprise Value$303.62M
Total Cash (Recent Filing)$248.98M
Total Debt (Recent Filing)$2.21M
Price to Earnings (P/E)-4.9
Beta1.81
Next Earnings
Aug 06, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding55,933,827
10 Day Avg. Volume816,106
30 Day Avg. Volume838,150
Standard Deviation0.29
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.01
Forecast
1Y Price Target
$26.22Price Target Upside166.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Olema Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPalazestrant and ribociclib combination demonstrates a high clinical benefit rate, indicating strong potential in the treatment of advanced ER+ breast cancer.
Drug Safety And InteractionPalazestrant and ribociclib combination's safety profile and lack of drug-drug interactions position it as a competitive option in the market.
Strategic CollaborationsThe expanded clinical collaboration and supply agreement with Novartis underscores confidence in the potential of the palazestrant and ribociclib combination.
Bears Say
Drug SafetyThe rate of neutropenia in the study was 58% with 37% of events being Grade 3, raising some concerns about the safety profile of the drug combination.
Financial HealthOLMA reported 1Q24 results with a net loss of ($31MM).
Financial SustainabilityYears of Cash Left is approximately 2.8 years with an annualized cash burn of $100 million.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $5.02 and its highest was $17.79 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 79 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on May 08, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.539 by -$0.021.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.56.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 55,933,826 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.539. Following the earnings report the stock price went down -9.309%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 11M.
---
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.22 (166.46% Upside)
$26.22 (166.46% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 474.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $66.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.58%
12-Months-Change
Fundamentals
Return on Equity
-48.31%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$26.22
▲(166.46% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Scholar Rock Holding
―
Seres Therapeutics
―
TRACON Pharmaceuticals
―
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+103.39%
reiterated a buy rating 5 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +103.39% per trade.
---